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Development of Atopic Dermatitis in Mice
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Errol P. Prens4, Louis M. Havekes1,2,3 and Arnold P. Oranje4
Mice with transgenic expression of human apolipoprotein C1 (APOC1) in liver and skin have strongly increased
serum levels of cholesterol, triglycerides, and free fatty acids, indicative of a disturbed lipid metabolism.
Importantly, these mice display a disturbed skin barrier function, evident from increased transepidermal water
loss, and spontaneously develop symptoms of dermatitis including scaling, lichenification, excoriations, and
pruritus. Histological analysis shows increased epidermal thickening and spongiosis in conjunction with
elevated numbers of inflammatory cells (eosinophils, neutrophils, mast cells, macrophages, and CD4þ T cells)
in the dermis. In addition, affected mice have increased serum levels of IgE and show abundant IgEþ mast cells
in the dermis. Partial inhibition of disease could be achieved by restoration of the skin barrier function with
topical application of a lipophilic ointment. Furthermore, the development of atopic dermatitis in these mice
was suppressed by corticosteroid treatment. These findings in APOC1(þ /þ ) mice underscore the role of skin
barrier integrity in the pathogenesis of atopic dermatitis.
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INTRODUCTION
Atopic dermatitis (AD) is an itchy inflammatory dermatitis
with a chronic course with remissions and exacerbations.
AD occurs primarily in children, but persisting cases in adult-
hood as well as adult late-onset AD occur (Boguniewicz
et al., 2006; Mohrenschlager and Ring, 2006). Usually the
personal and/or family history of other atopic conditions,
such as asthma and allergic rhinitis, are positive. It is
estimated that about 20% of the population of the indus-
trialized countries has an atopic constitution, and between
5 and 20% suffers at least during some period of their life
from AD (Williams and Flohr, 2006). AD is mainly gene-
tically determined with at least 20 involved genes (Hoffjan
and Epplen, 2005). In addition, environmental factors are
considered of importance for the development of the disease.
Recent studies focus on the barrier function of the skin
(Proksch et al., 2006) and genetic defects of filaggrin (Palmer
et al., 2006).
Treatment of AD is largely confined to the application of
anti-inflammatory drugs such as corticosteroids; calcineurin
inhibitors are frequently prescribed as steroid sparing agents.
Because such treatments show a transient effect on symptoms
and do not mediate long-lasting immunosuppression of
disease, there is a great need of drugs that interfere with
initial triggers of the disease. The etiology of the disease is
unclear, although a major part of the patients show an
association with an allergic response evident from increased
levels of IgE (Novak et al., 2003; Leung et al., 2004). The
integrity of the skin barrier, in particular the composition of
the stratum corneum, appears to be of great importance for
the development and progression of skin lesions in patients
with AD (Proksch et al., 2006; Segre, 2006). The composition
of the stratum corneum is dependent on lipid homeostasis
and therefore it was of importance to observe that mice
transgenic for human apolipoprotein C1 (APOC1) have
disturbed serum levels of lipids and spontaneously develop
dermatitis; at older age, mice develop severe dermatitis with
moderate epidermal hyperplasia and hyper- and parakera-
tosis (Jong et al., 1998). APOC1 is an apolipoprotein involved
in lipoprotein metabolism (Jong et al., 1999). In healthy
individuals, the protein is predominantly expressed in liver,
skin, and brain tissue with macrophages and keratinocytes as
major cell types. The protein is highly conserved and a high
degree of homology exists between APOC1 in mice and man.
APOC1(þ /þ ) mice have increased levels of free fatty acids,
cholesterol, and triglycerides, but show complete absence of
subcutaneous fat and atrophic sebaceous glands. Herein, we
demonstrate that APOC1(þ /þ ) mice display a disturbed skin
barrier function and develop symptoms of AD that are
sensitive to corticosteroid treatment.
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RESULTS
Development of dermatitis
Regardless of gender, human APOC1(þ /þ ) transgenic mice
develop signs of AD, comprising scaling, lichenification, and
papules, and mild-to-severe excoriations from an age of 6
weeks onward. Figure 1 shows typical examples of mice with
progressed dermatitis. In contrast, APOC1(þ /) heterozy-
gous mice do not show such symptoms. In APOC1(þ /þ )
mice, aspects of dermatitis are particularly evident in the
upper dorsal skin, but when mice grow older also the head
and eyelids may become affected. To assess the severity of
dermatitis, the upper dorsal skin was evaluated employing a
3-item score by assigning 0–3 points to each of the following
items: scaling, lichenification/papules, and excoriations. At
an age of about 6 weeks, mice display only mild signs
of scaling with a clinical severity score ranging from 0 to 2
(mild dermatitis). From this age onward the severity of the
dermatitis develops gradually with increasing edema/
infiltration classified as lichenification (moderate dermatitis)
and excoriations. At an age of 12 weeks most of the mice
have progressed to a severity score ranging from 4 to 7.
Involvement of inflammatory cells
To gain more insight into the underlying mechanism of
dermatitis in these mice, skin sections from the upper dorsal
area of APOC1(þ /þ ) mice were evaluated with regard to
hyperplasia and the presence of inflammatory cells. Figure 2a
shows that dermatitis is associated with thickening of
epidermis and dermis. In addition, more than 90% of the
mice showed mild-to-moderate spongiosis from an age of 6
weeks onward (Figure 2a, insert). At an age of 6 weeks,
various inflammatory cell types are increased in number in
APOC1(þ /þ ) mice as compared to APOC1(þ /) mice.
This was demonstrated for eosinophils, mast cells, CD4þ
T cells, and macrophages. Figure 2 shows the increased
involvement of neutrophils and eosinophils (Figure 2b), mast
cells (Figure 2c), CD4þ T cells (Figure 2g), and CD11bþ
macrophages (Figure 2h) in the skin of 12-week-old
APOC1(þ /þ ) mice, as compared to age-matched
APOC1(þ /) mice (Figure 2e–f and j–k). Results in wild-
type mice were similar to those in APOC1(þ /) mice (data
not shown). Increased numbers of eosinophils are already
found at early age when they outnumber neutrophils
(Figure 3). Numbers of mast cells are increased at young
age, and these numbers further increase during disease
progression (Figure 4a); part of the mast cells show
degranulation (Figure 2c, arrow). Because this may be due
to cross-linking of IgE receptors, we evaluated the involve-
ment of IgE. At an age of 8 weeks, IgE serum levels in
APOC1(þ /þ ) mice were on average 0.77±0.93 mgml1
and comparable to the levels in age-matched APOC1(þ /)
or wild-type mice. As shown in Figure 4b, serum levels of
IgE increase in APOC1(þ /þ ) mice in parallel with
disease progression. At an age of 12 weeks, serum levels
of IgE in APOC1(þ /þ ) mice were 7.05±4.00 mgml1 and
significantly higher than those in APOC1(þ /) mice
(2.09±1.89 mgml1; Po0.01) or wild-type mice (1.00±
0.91 mgml1; Po0.01). From an age of 12 weeks onward
mast cells in the dermis become IgE-positive (Figure 2i).
A gradual increase in numbers of IgEþ mast cells correlated
with the appearance of IgE in serum (Figure 4c). As shown in
Figure 5, epidermal hyperplasia is already found at an early
age; disease progression is associated with increased
thickening of the epidermis.
Disturbed skin barrier function as an underlying cause
of dermatitis in APOC1(þ /þ ) mice
APOC1(þ /þ ) mice show a disturbed lipid metabolism, lack
of subcutaneous fat, and atrophic sebaceous glands, and it
might therefore be that this condition affects the quality of the
skin barrier. We verified the integrity of the skin barrier by
determining transepidermal water loss (TEWL).
Figure 6 shows the results of measurements in individual
mice at an age of 12 weeks. Normal TEWL values in wild-
type mice or in APOC1(þ /) mice range from 10 to
Figure 1. Appearance of atopic dermatitis in APOC1(þ /þ ) mice. AD in
APOC1(þ /þ ) mice is associated with scaling, papules, lichenification, and
excoriations. Upper panel, 12-week-old APOC1(þ /þ ) mouse; middle panel,
18-week-old APOC1(þ /þ ) mouse; lower panel, 12-week-old APOC1(þ /)
control mouse.
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15 g h1m2. However, APOC1(þ /þ ) mice at an age of
12 weeks have a four-fold higher TEWL. At an age of
3 weeks, APOC1(þ /þ ) mice already show increased
TEWL of 17.2±1.9 g h1m2 as compared to a value of
11.7±2.4 g h1m2 in heterozygous littermates of the same
age (Po0.0005). Subsequently, a further increase develops
gradually (data not shown). Because ointments may have a
beneficial effect in the treatment of AD patients, we were
interested whether basic creams frequently used in clinical
practice would have an influence on the TEWL. We
compared 20% petrolatum in cetomacrogolus cream as a
lipophilic ointment with a hydrophilic moisturizing cream
that is comparable to the cream used for the formulation of
triamcinolone acetonide (TCA; see also Figure 8). As shown
in Figure 6a, mice subjected to 3 weeks of treatment with
20% petrolatum showed diminished loss of barrier function;
the moisturizing hydrophilic cream was ineffective in this
respect. In a separate experiment, 3 weeks of treatment with
20% petrolatum diminished TEWL and this effect was
associated with a decreased severity of dermatitis according
to the three-item severity score (TIS; Figure 6b).
APOC1(þ /þ ) mice display increased pruritus
As indicated above, APOC1(þ /þ ) mice develop increased
numbers of IgEþ mast cells in the dermis during progression
of disease. Therefore, individual APOC1(þ /þ ) mice were
monitored with regard to scratching behavior employing a
system based on movements of unique frequency between 18
and 25Hz. Mice were housed individually in a cage fitted on
a platform and monitored overnight for a period of 12 hours.
Both the number of scratch events and the duration of
scratching were monitored. According to this system,
APOC1(þ /) heterozygous littermates, which do not deve-
lop clinical symptoms of dermatitis, show a baseline scratch
frequency ranging between 5 and 25 scratches per hour.
APOC1(þ /þ ) mice show an increased frequency of
scratching (and duration; not shown) at an age of 9 weeks
and a further increase while disease progresses (Figure 7).
Sensitivity of dermatitis in APOC1(þ /þ ) mice toward
treatment with corticosteroids
To evaluate whether the development of dermatitis
in APOC1(þ /þ ) mice was sensitive to treatment with
APOC1(+/+)
APOC1(+/–)
APOC1(+/+)
APOC1(+/+)
APOC1(+/–)
a b c
d e f
g h i
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Figure 2. Histopathology of AD. Mice were killed at an age of 12 weeks and skin sections were evaluated with respect to epidermal hyperplasia
(a and d, hematoxyllin/eosin staining), the presence of eosinophils (arrows) and neutrophils (b and e; LUNA staining), mast cells (c and f; toluidin blue staining),
CD4þ T cells (g and j), CD11bþ cells (h and k), and IgEþ cells (i and l). (a–c and g–I) The results for APOC1(þ /þ ) mice, whereas (d–f and j–l) show the
staining of tissues from APOC1(þ /) controls. (m–o) The isotype controls for CD4, CD11b, and IgE, respectively. The insert of (a) shows an example of
spongiosis at an age of 12 weeks. The arrow in (c) indicates degranulation of mast cells. Bar¼ 50 mm in (b, c, e, and f) and the insert of (a); bar¼ 100 mm in all
other panels.
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corticosteroids, mice were treated for a period of 3 weeks by
daily topical application of 0.1% TCA or a hydrophilic
moisturizing cream (Lanette cream, see Materials and
Methods). As shown in Figure 8a, TCA treatment inhibited
epidermal hyperplasia and caused rather a thinning of the
epidermis, a well-known adverse effect associated with
prolonged exposure to corticosteroids. We also evaluated
numbers of inflammatory cells and found that treatment with
TCA diminished numbers of granulocytes, CD11bþ macro-
phages, and CD4þ T cells (Figure 8b); numbers of mast cells
were not different from mice left untreated or from mice
treated with the moisturizing cream.
DISCUSSION
Mice with transgenic overexpression of human APOC1
develop a skin disease that is characterized by a variety of
features resembling AD. As reported earlier by Jong et al.
(1998), the epidermis of APOC1(þ /þ ) mice shows an
altered lipid composition as compared to wild-type mice,
with decreased levels of triglycerides, wax diesters, and
lanosterol, increased levels of free fatty acids and free
cholesterol, and no differences in ceramides and polar lipids.
Possibly, local overexpression of APOC1 also prevents the
production of sebum. It is likely that these factors are
responsible for a disturbed skin barrier function, and this
was substantiated by demonstrating increased TEWL at an
age of 3 weeks immediately after weaning. Although it is
tempting to speculate that a change in housing conditions is
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Figure 3. Dynamics of inflammatory cells in APOC1(þ /þ ) mice.
Mice were killed at different ages starting at an age of 6 weeks, and tissue
sections were evaluated with respect to the number of eosinophils and
neutrophils. Individual APOC1(þ /þ ) mice are indicated with filled circles;
results of APOC1(þ /) and wild-type mice are indicated as triangles and
open circles, respectively. For each individual mouse, three non-serial
sections were evaluated (10 sequential microscopic views per section). Each
symbol represents an individual mouse with the mean number of cells per
microscopic view at a 1000 magnification. For statistical analysis data
obtained in 5- and 6-week-old mice were combined; the same was done
for 8- and 9-week-old mice. The Kruskal–Wallis test showed significant
differences for eosinophils (Po0.0005) and neutrophils (Po0.00005).
At all time points, both cell types were significantly increased as compared to
wild-type mice or APOC1(þ /) mice (Mann–Whitney U-test, Po0.01).
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Figure 4. AD in APOC1(þ /þ ) mice: mast cells and IgE. Mice were killed at
different ages starting at an age of 6 weeks, and tissue sections were evaluated
with respect to the number of (a) mast cells or (c) IgEþ cells. Individual
APOC1(þ /þ ) mice are indicated with filled circles. Heterozygous
APOC1(þ /) mice (triangles) or / wild-type mice (open circles), which do
not develop AD, are included as controls. (b) IgE levels were tested by ELISA
as described in Materials and Methods. For each individual mouse, three
non-serial sections were evaluated (10 sequential microscopic views per
section). Each symbol represents an individual mouse with the mean number
of cells per microscopic view at a  400 magnification. (c) Number of
IgEþ cells was determined and for each individual mouse it was plotted
against the corresponding serum value. For statistical analysis, data obtained
in 5- and 6-week-old mice were combined; the same was done for 8- and
9-week-old mice. The Kruskal–Wallis test showed significant differences for
mast cells (Po0.00001) and for IgE (Po0.01). At all time points, numbers
of mast cells were significantly increased (Mann–Whitney U-test, Po0.01),
as compared to wild-type mice or APOC1(þ /) mice. Differences as
compared to week 5/6 are indicated in the figure.
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responsible for the subsequent onset of dermatitis, this could
not be attributed to an influence of temperature and humidity
inasmuch as these factors remained constant. Because
specific pathogen-free APOC1(þ /þ ) mice that are not
subject to a change in housing conditions show similar
development of dermatitis, it is more likely that loss of
integrity of the skin barrier facilitates exposure of innate
immune cells to environmental antigens (e.g. commensal
skin microorganisms) and the subsequent development of an
inflammatory response. APOC1(þ /þ ) mice already show at
an early age that TEWL, inflammatory cells, and epidermal
hyperplasia are increased, and therefore it is difficult to
conclude with certainty which event represents the initial
trigger of the disease. Topical treatment with a lipophilic
ointment improved several aspects of dermatitis, most likely
by partial restoration of the skin barrier function and by
preventing exposure to environmental antigens. Similarly,
beneficial effects of emollients have been observed
in patients (Loden, 2005).
The inflammatory response in APOC1(þ /þ ) mice shows
similarity to the response that takes place after epicutaneous
sensitization with ovalbumin, where AD-like disease is
characterized by increased numbers of eosinophils, mast
cells, preferential infiltration by CD4þ T cells, spongiosis,
and comparably increased levels of serum IgE (Wang et al.,
2007). In addition, epicutaneous exposure to ovalbumin was
associated with local upregulation of mRNA encoding IL-4,
IL-5, and IFN-g (Spergel et al., 1998), with an essential role
for IL-13 in the induction of a Th2 response (Herrick et al.,
2003). Recent interest has also implicated thymic stromal
lymphoprotein—a cytokine produced by keratinocytes and
responsible for local activation of skin dendritic cells—in
the pathogenesis of AD and the development of Th2 cells
(Yoo et al., 2005). Therefore, studies focused on the
local expression of Th2-promoting factors in the skin of
APOC1(þ /þ ) mice may help to gain insight into the
pathogenesis of the disease in this particular model. In this
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Figure 5. Increased epidermal thickening during progression of dermatitis in
APOC1(þ /þ ) mice. Heterozygous APOC1(þ /) mice (triangles) or /
wild-type mice (open circles), which do not develop AD, are included as
controls. For each individual mouse, three non-serial sections were evaluated
and for each section the epidermal thickness was determined (10
measurements with an interval of 250 mm). For each individual mouse, the
average thickness of 30 measurements is shown. For statistical analysis, data
obtained in 5- and 6-week-old mice were combined; the same was done for
8- and 9-week-old mice. The Kruskal–Wallis test showed a significant
difference between the groups (Po0.00005). At all time points, epidermal
thickness was significantly increased (Mann–Whitney U-test, Po0.01) as
compared to wild-type mice or APOC1(þ /) mice. Differences as compared
to week 5/6 are indicated in the figure.
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Figure 6. Increased TEWL in APOC1(þ /þ ) mice: effect of lipophilic
ointment. (a) TEWL was evaluated in the upper dorsal area of 12-week-old
APOC1(þ /þ ) mice left untreated or after treatment by topical application
(daily, 3 weeks) with 20% petrolatum in cetomacrogolus cream or a
moisturizing cream; APOC1(þ /) mice were included as controls. In a
separate experiment, 9-week-old APOC1(þ /þ ) mice were left untreated
(filled circles) or treated for a period of 3 weeks with 20% petrolatum in
cetomacrogolus cream (open circles), and evaluated with respect to TEWL
(b) and the severity of dermatitis according to the TIS score (c).
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Figure 7. The development of AD in APOC1(þ /þ ) mice is associated with
pruritus. Mice (n¼ 8) were included at an age of 9 weeks and individually
monitored at weekly intervals with respect to their scratching behavior,
as described in Materials and Methods. Results are expressed as group
means±SEM. The triangle indicates the mean number of scratches per hour
in 9-week-old heterozygous APOC1(þ /)mice. Changes in scratch
frequency were evaluated with the Wilcoxon signed ranks test. P-values
show significant differences as compared to the values at ages of 9 and
10 weeks.
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respect, the possibility that overexpression of APOC1 has a
modulating effect on innate immunity and the development
of a Th2 type of inflammatory response needs further
investigation.
Progression of disease in APOC1(þ /þ ) mice occurred in
conjunction with the development of pruritus, in particular
from an age of 9 weeks onward when mice developed
increased levels of IgE in serum and IgEþ mast cells in the
dermis. This suggests that pruritus increases particularly by
activation of mast cells once they have bound IgE on their
surface. Because these events occur later than infiltration by
inflammatory cells and epidermal thickening, we consider
scratching as a consequence rather than a primary cause of
dermatitis in this model.
APOC1(þ /þ ) mice share many features with AD in
humans; however, there are several differences as well. First
of all, the stratum corneum of patients has decreased cera-
mide levels and this was not observed in APOC1(þ /þ )
mice (Jong et al., 1998). Secondly, increased plasma levels
of APOC1, cholesterol, triglycerides, and free fatty acids
are not typical for AD. It remains to be established whether
AD in patients is associated with the upregulation of
APOC1 in the skin. The involvement of neutrophils is also
different from the clinical situation; this may occur in the
APOC1(þ /þ ) mouse because pruritus was left untreated
and this condition could promote an inflammatory response,
for example, to microorganisms associated with the skin. On
the other hand, many relevant aspects (elevated eosinophils,
IgE, CD4þ T cells, macrophages, mast cells, spongiosis, and
pruritus) are involved and several of these aspects were
sensitive to TCA. Preliminary data indicate that dermatitis
in this model is also sensitive to topical treatment with
fluticasone proprionate or tacrolimus (Oranje et al., sub-
mitted for publication), and to oral treatment with dexa-
methasone. These findings substantiate an important role of
T cells and macrophages and the usefulness of the APOC1
model to evaluate underlying mechanisms in AD.
MATERIALS AND METHODS
Mice
Human APOC1(þ /þ ) transgenic mice were generated as described
previously (Jong et al., 1998) employing breeding couples of female
APOC1(þ /) and male APOC1(þ /þ ) mice. From two transgenic
lines, line 11/1 was selected because it showed the highest
expression of APOC1 with the highest plasma lipid levels.
Heterozygous APOC1(þ /) mice were derived from the same
breeding stock. Wild-type C57BL/6 mice were derived from a
colony, housed under the same conditions. Animals were housed in
Hydrophilic cream 0.1% TCAUntreated
N
um
be
r o
f c
el
ls/
m
icr
os
co
pi
c 
vie
w
Granulocytes 
P<0.005
Mast cells 
0
20
40
60
CD11b 
0
10
20
30
0
5
10
15
CD4
0
1
2
3
4
P<0.05
P<0.05
Figure 8. Inhibition of epidermal hyperplasia and inflammation by TCA. APOC1(þ /þ ) mice, 9 weeks of age, were included and left untreated or subjected
to daily topical treatment with 0.1% TCA or moisturizing cream. Treatment resulted in significant (a) inhibition of epidermal thickening and (b) inhibition
of infiltration with inflammatory cells (& untreated, J 0.1% TCA, n moisturizing cream). Bar¼ 100 mm.
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individually ventilated cages until an age of 6 weeks and
subsequently maintained under clean conventional conditions.
These housing conditions were comparable in terms of temperature
(211C) and humidity (55%). All of these studies were performed with
the approval of the Animal Welfare Committee and in compliance
with Dutch governmental regulations on animal experimentation.
TIS score and thickening of the skin
Mice were monitored regarding the progression of dermatitis with
the use of a TIS score adapted from Wolkerstorfer et al. (1999)
comprising the following items: scaling, papules and lichenification,
excoriations. Each of the items were graded from 0 (normal) to
3 (severe), and included in a TIS scale ranging from 0 to 9. A TIS of
7 and above is considered unacceptable for reasons of animal
welfare and accordingly mice were killed if such a clinical condition
developed.
At different time points mice were evaluated with respect to the
thickness of a fold of skin in the upper dorsal area, employing a
caliper (Mitutoyo, Veenendaal, The Netherlands).
Treatment
Where indicated mice were treated for a period of 3 weeks by daily
topical application of approximately 70mg of 0.1% TCA (Pharma-
chemie, Haarlem, The Netherlands; composition: 0.1% TCA, 15%
cetomacrogol wax, 20% Cetiol V, 4% sorbitol, 0.2% sorbic acid,
60.8% water). Control groups were treated with 20% petrolatum in
cetomacrogolus cream (Fagron Pharmaceuticals BV, Nieuwerkerk
a/d IJssel, The Netherlands; composition: 20% petrolatum, 16% Cetiol
V, 12% cetomacrogol emulsifier; 3.2% sorbitol, 0.16% sorbic acid,
48.6% water) or moisturizing cream (Lanette cream, Pharmachemie;
composition: 20% Cetiol V, 15% cetostearylalcohol emulgator B,
4% sorbitol, 0.15% sorbic acid, 60.9% water).
Transepidermal water loss
TEWL was measured by placing a 12-mm detection probe of a
skin evaporative water recorder (Tewameters TM 300, Courage &,
Khazaka, Cologne, Germany) on the upper dorsal skin area of each
individual mouse. Measurements were performed at 55% humidity
and at a temperature of 211C. Results were recorded when TEWL
readings were stabilized, that is approximately 1minute after the
probe had been placed on the skin. If mice were subjected to topical
treatment, TEWL measurements were performed 24 hours after
treatment.
Histology
Skin tissue derived from the upper dorsal area was fixated with
formaldehyde and embedded in paraffin. For the measurement of
epidermal thickness, 5mm sections were stained with hematoxy-
lin-eosin-saffron and the thickness of the epidermis was determined
via microscopic field analysis using a metric ocular (Zeiss, Sliedrecht,
The Netherlands). For each individual mouse, three non-sequential
sections were evaluated and for each section the epidermal thickness
was determined by 10 sequential measurements with intervals of
250mm. Numbers of neutrophils and eosinophils were evaluated by
differential counting after LUNA staining at a  1000 magnification.
Results are expressed as numbers of cells per microscopic view of
50mm2. Mast cells were evaluated after staining of tissue sections with
toluidin blue, at a magnification of  400 (microscopic view of
190mm2). CD4þ T cells, IgEþ cells, and macrophages were
determined by immunostaining of cryopreserved tissues with rat
anti-mouse CD4 (dilution 1:100; BD Biosciences, San Diego, CA),
followed by incubation with biotinylated goat anti-rat Ig (dilution
1:200, BD Biosciences), biotin-labeled rat anti-mouse IgE (dilution
1:800; BD Biosciences), and biotin-labeled rat anti-mouse CD11b
(dilution 1:1000; BD Biosciences), respectively. After incubation,
biotinylated antibodies were detected by incubation with streptavidin-
HRP (dilution 1:500; Vector Laboratories, Burlingame) using
3-amino-9-ethylcarbozole (Sigma, St Louis, MO) as a substrate.
Corresponding rat Ig2a and IgG2b isotype controls (BD Biosciences)
were used to verify for background staining. Cells visualized
by immunostaining were counted at a  400 magnification (micro-
scopic view of 190mm2).
ELISA
Levels of mouse IgE in serum were determined by ELISA (BD OptEIA
kit, BD Biosciences). Samples were tested at 1:100 and 1:1000
dilutions. Results are expressed in mgml1.
Statistical analysis
All statistical analyses were performed using the statistical software
program SPSS 11.5 for Windows (SPSS Inc., Chicago, IL). Differences
between groups were evaluated using the Kruskal–Wallis test,
followed by the Mann–Whitney U-test. Changes within individual
mice were evaluated with the Wilcoxon signed ranks test.
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